1 completed, 1 recruiting, 1 terminated. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 1, Recruiting 1, Terminated 1 |
| Phase 2 | 3 | Completed 1, Recruiting 1, Terminated 1 |
Follow Warm Autoimmune Hemolytic Anemia: new trials by email Literature Review of Warm Autoimmune Hemolytic Anemia trials Research Report on Warm Autoimmune Hemolytic Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease CTX112 - Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia | Phase 1 / Phase 2 | Recruiting | CRISPR Therapeutics AG | 60 | 2026-07-17 | 2026-10-20 |
| An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias (RUBY-4) Povetacicept - Idiopathic Thrombocytopenic Purpura, Immune Thrombocytopenia | Phase 1 / Phase 2 | Completed | Alpine Immune Sciences Inc, A Subsidiary of Vertex | 30 | 2023-07-03 | 2026-09-14 |
| A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA) ALXN1830 - Warm Autoimmune Hemolytic Anemia | Phase 1 / Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | 8 | 2018-01-10 | 2020-05-13 |
Purpura, Thrombocytopenic, Idiopathic (2) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Autoimmune (1)
Autoimmune Diseases (2) · Blood Coagulation Disorders (2) · Blood Platelet Disorders (2) · Cytopenia (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Hemorrhage (2) · Hemorrhagic Disorders (2) · Immune System Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Purpura (2) · Purpura, Thrombocytopenic (2) · Signs and Symptoms (2) · Skin Manifestations (2)
orilanolimab (1)
Alexion Pharmaceuticals, Inc. (1) · Alpine Immune Sciences Inc, A Subsidiary of Vertex (1) · CRISPR Therapeutics AG (1)
United States (3) · Germany (2) · Spain (2) · Australia (1) · Austria (1) · Canada (1) · Italy (1) · Jordan (1) · Norway (1) · Turkey (Türkiye) (1) · United Kingdom (1)
2023 (1)